# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13G**

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )

# **Unum Therapeutics Inc.**

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

903214104 (CUSIP Number)

December 31, 2018 (Date of Event Which Requires Filing of this Statement)

□ Rule 13d-1(b)
 □ Rule 13d-1(c)
 ☑ Rule 13d-1(d)
 (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS					
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	New Leaf Ventures III, L.P.					
2	CHECK TH	ΕΑ	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
		b) 🛭				
3	SEC USE O	NLY				
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION			
-	CITIZEIVOI	、	SKILINGE OF OKOMINEMION			
	Delaware					
	Belaware	5	SOLE VOTING POWER			
		J	SOLE VOTING TOWER			
			0			
	JMBER OF	6	SHARED VOTING POWER			
	SHARES NEFICIALLY		SIMILD VOINGTOWER			
			897,773(1)			
OWNED BY EACH		7	SOLE DISPOSITIVE POWER			
REPORTING		/	SOLE DISPOSITIVE FOWER			
	PERSON		0			
	WITH	8	SHARED DISPOSITIVE POWER			
		0	SHARED DISPOSITIVE POWER			
			007 772(1)			
_	A CORECAS		897,773(1)			
9	AGGREGA	IE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	007 777(1)					
4.0	897,773(1)		A CODE CATE ANOTHER BY BOLL (A) TWO LIDES CERTAIN (MADES (CERTAINS)			
10	CHECK IF	THE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	PERCENT (	OF (	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	3.0%(2)					
12	TYPE OF R	EPC	ORTING PERSON (SEE INSTRUCTIONS)			
	PN					

- All such shares are held of record by NLV III (as defined in Item 2(a) below). NLVA III (as defined in Item 2(a) below) is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III (as defined in Item 2(a) below) is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of Hunt, Lathi, and Ratcliffe (each as defined in Item 2(a) below), the managing directors of NLV Management III (collectively, the "NLV Managing Directors") may each be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1						
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
			re Associates III, L.P.			
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) [] (1	o) [2				
3	SEC USE O	NIT X	7			
3	SEC USE O	INL				
4	CITIZENSH	IID (	OR PLACE OF ORGANIZATION			
7	CITIZEIVOI	.11 (	SKILINGE OF ONOMINIZATION			
	Delaware					
		5	SOLE VOTING POWER			
NU	JMBER OF		0			
	SHARES	6	SHARED VOTING POWER			
	NEFICIALLY					
O	WNED BY	7	897,773(1)			
Di	EACH		SOLE DISPOSITIVE POWER			
	EPORTING PERSON		0			
	WITH	8	SHARED DISPOSITIVE POWER			
		O	SHARED DISPOSITIVE FOWER			
			897,773(1)			
9	AGGREGA	ΓΕ Α	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	897,773(1)					
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	3.0%(2)					
12		ED(	OPTING DEDSON (SEE INSTRICTIONS)			
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
	DN					

- (1) All such shares are held of record by NLV III. NLVA III is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may each be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1	NAMES OF REPORTING PERSONS					
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	New Leaf B	ioph	arma Opportunities I, L.P.			
2	CHECK TH	ΕA	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
		b) [2				
3	SEC USE O	NLY	7			
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION			
7	CITIZLIVOI	111 \	SKI ENGE OF OKONIVENTION			
	Delaware					
	Belaware	5	SOLE VOTING POWER			
		J	SOLE VOTINGTOWER			
	JMBER OF	6	SHARED VOTING POWER			
	SHARES NEFICIALLY	U	SIMILD VOING FOWER			
			897,772(1)			
OWNED BY EACH		7	SOLE DISPOSITIVE POWER			
RI	EPORTING	/	SOLE DISPOSITIVE POWER			
	PERSON					
	WITH	8	SHARED DISPOSITIVE POWER			
		O	SHARED DISPOSITIVE POWER			
			007 772(1)			
0	A CORECAS	T.E.	897,772(1)			
9	AGGREGA	IE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	007 772(1)					
10	897,772(1)					
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11	PERCENT (	JF (	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	3.0%(2)					
12	TYPE OF R	EPC	DRTING PERSON (SEE INSTRUCTIONS)			
	PN					

- (1) All such shares are held of record by Biopharma I (as defined in Item 2(a) below). NLBA I (as defined in Item 2(a) below) is the general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLBA I and ultimate general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may each be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1	NAMES OF REPORTING PERSONS					
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
			Associates I, L.P.			
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) □ (l	b) 🛭				
3	SEC USE O	NLY	I			
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION			
	D 1					
	Delaware	_	COLE MOTING POMER			
		5	SOLE VOTING POWER			
			0			
	JMBER OF	6	SHARED VOTING POWER			
	SHARES NEFICIALLY	U	SHARED VOTING FOWER			
	WNED BY		897,772(1)			
O	EACH	7	SOLE DISPOSITIVE POWER			
RI	EPORTING	,	SOLE BIST GOTTY ET GWEK			
	PERSON		0			
	WITH	8	SHARED DISPOSITIVE POWER			
			897,772(1)			
9	AGGREGA	ΓΕ Α	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	897,772(1)					
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	B 884 :=:					
	3.0%(2)					
12	TYPE OF R	EPC	ORTING PERSON (SEE INSTRUCTIONS)			
	DNI					
	PN					

- (1) All such shares are held of record by Biopharma I. NLBA I is the general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLBA I and ultimate general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may each be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1 NAMES OF DEPODEING DEDCONS

1	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	New Leaf Venture Management III, L.L.C.						
2		E A b) [2	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ☑				
	` `						
3	SEC USE O	NLY	$\ell$				
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION				
	Delaware						
		5	SOLE VOTING POWER				
	UMBER OF	-					
	SHARES NEFICIALLY	6	SHARED VOTING POWER				
O,	WNED BY	-	1,795,545(1)				
RI	EACH EPORTING	7	SOLE DISPOSITIVE POWER				
	PERSON WITH		0				
	VV 1111	8	SHARED DISPOSITIVE POWER				
			1,795,545(1)				
9	AGGREGA	TE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	1,795,545(1)						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	6.0%(2)						
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	00						

- (1) 897,773 of such shares are held of record by NLV II. NLVA II is the general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA II and ultimate general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. 897,772 of such shares are held of record by Biopharma I. NLBA I is the general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLBA I and ultimate general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1	NAMES OF REPORTING PERSONS						
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Ronald M. Hunt						
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) $\Box$ (1	b) 🛭					
3	SEC USE O	NLY					
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION				
	United State	S					
		5	SOLE VOTING POWER				
NU	JMBER OF		0				
	SHARES	6	SHARED VOTING POWER				
	NEFICIALLY						
OWNED BY			1,795,545(1)				
EACH		7	SOLE DISPOSITIVE POWER				
	EPORTING PERSON						
	WITH		0				
	VV 1 1 1 1	8	SHARED DISPOSITIVE POWER				
			1,795,545(1)				
9	AGGREGA	IE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	1 705 5 45(4)						
10	1,795,545(1)						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
11							
11	1 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	C 00/(2)						
10	6.0%(2)	EDC	ADTING DEDCON (CEE INCTDICTIONS)				
12	IYPE OF R	EPC	ORTING PERSON (SEE INSTRUCTIONS)				
	IN						

- (1) 897,773 of such shares are held of record by NLV II. NLVA II is the general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA II and ultimate general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. 897,772 of such shares are held of record by Biopharma I. NLBA I is the general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLBA I and ultimate general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1	NAMES OF REPORTING PERSONS						
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Vijay K. Lathi						
2	CHECK TH	ΕА	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
		b) [	· · · · · · · · · · · · · · · · · · ·				
		- /					
3	SEC USE O	NII X	7				
3	SEC USE U	INL.					
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION				
	United State	S					
		5	SOLE VOTING POWER				
			0				
	JMBER OF	6	SHARED VOTING POWER				
	SHARES	U	SHAKED VOTING POWER				
	NEFICIALLY						
OWNED BY			1,795,545(1)				
EACH		7	SOLE DISPOSITIVE POWER				
	EPORTING						
	PERSON		0				
	WITH	8	SHARED DISPOSITIVE POWER				
		-					
			1,795,545(1)				
0	ACCRECAS	PP.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	AGGREGA	IE /	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	1,795,545(1)						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	TERCENT OF CENTED BY THROUGH HAROW (6)						
	6.0%(2)						
17		EDC	ADTING DEDCON (SEE INSTRUCTIONS)				
12	I I PE OF R	LP(	ORTING PERSON (SEE INSTRUCTIONS)				
	IN						

- (1) 897,773 of such shares are held of record by NLV II. NLVA II is the general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA II and ultimate general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. 897,772 of such shares are held of record by Biopharma I. NLBA I is the general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLBA I and ultimate general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (2) Based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018.

1	NAMES OF REPORTING PERSONS					
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	INCO. IDENTIFICATION NO. OF THOSE PERSONS (ENTITLES ONE)					
	Liam T. Rate	cliff	e			
2	CHECK TH	ΕА	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
		o) [	· · · · · · · · · · · · · · · · · · ·			
	(a) — (.	- ر	_			
3	SEC USE O	NL:	Y			
1	CITIZENCI	IID /	OR PLACE OF ORGANIZATION			
4	CITIZENSE	IIP (	OR PLACE OF ORGANIZATION			
	United State	S				
		5	SOLE VOTING POWER			
		J	SOLE VOING TOWER			
NI	JMBER OF		8,475(1)			
	SHARES	6	SHARED VOTING POWER			
	NEFICIALLY					
			4.707.7.17.00			
OWNED BY			1,795,545(2)			
EACH		7	SOLE DISPOSITIVE POWER			
RI	EPORTING					
	PERSON		8,475(1)			
	WITH					
	VV 1 1 1 1	8	SHARED DISPOSITIVE POWER			
			1,795,545(2)			
9	ACCDECA	rr .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
9	AGGREGA		AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,804,020(1)	(2)				
10	CHECK IF	ГНЕ	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
	OIII OII II					
11	PERCENT (	OF (	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	5.00(/3)					
	6.0%(3)					
12	TYPE OF R	EPC	DRTING PERSON (SEE INSTRUCTIONS)			
	IN					

- (1) The shares reported in row 5 and 7 above consist of Common Stock underlying a stock option directly owned by Ratcliffe and exercisable within 60 days of December 31, 2018.
- (2) 897,773 of the shares reported in rows 6 and 8 are held of record by NLV II. NLVA II is the general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA II and ultimate general partner of NLV II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. 897,772 of the shares reported in rows 6 and 8 are held of record by Biopharma I. NLBA I is the general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLBA I and ultimate general partner of Biopharma I and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities.
- (3) Based on 29,997,947 shares of Common Stock, calculated as follows: (i) 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 13, 2018, plus (ii) 8,475 shares of Common Stock subject to stock option awards that have been granted to Mr. Ratcliffe in his capacity as a director of the Issuer and that are exercisable as of or within 60 days after December 31, 2018.

#### Schedule 13G

#### Item 1(a). Name of Issuer:

Unum Therapeutics Inc. (the "Issuer").

#### Item 1(b). Address of Issuer's Principal Executive Offices:

200 Cambridge Park Drive, Suite 3100 Cambridge, MA 02140

#### Item 2(a). Name of Persons Filing:

This joint statement on Schedule 13G is being filed by New Leaf Ventures III, L.P. ("NLV III"), New Leaf Venture Associates III, L.P. ("NLVA III"), New Leaf Venture Management III, L.L.C. ("NLV Management III"), New Leaf Biopharma Opportunities I, L.P. ("Biopharma I") and New Leaf BPO Associates I, L.P. ("NLBA I" and together with NLV III, NLVA III, NLV Management III and Biopharma I, the "Reporting Entities"), Ronald M. Hunt ("Hunt"), Vijay K. Lathi ("Lathi") and Liam T. Ratcliffe ("Ratcliffe" and, together with Hunt and Lathi, the "Reporting Individuals"). The Reporting Entities and the Reporting Individuals collectively are referred to as the "Reporting Persons".

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons (other than Lathi) is New Leaf Venture Partners, Times Square Tower, 7 Times Square, Suite 3502, New York, NY 10036.

The address of the principal business office of Lathi is New Leaf Venture Partners, 1200 Park Place, Suite 300, San Mateo, CA 94043.

#### Item 2(c). <u>Citizenship</u>:

Each of NLV III, NLVA III, Biopharma I and NLBA I is a limited partnership organized under the laws of the State of Delaware.

NLV Management III is a limited liability company organized under the laws of the State of Delaware.

Each Managing Director is a citizen of the United States.

#### Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.001 par value per share ("Common Stock").

#### Item 2(e). CUSIP Number:

903214104

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

Item 4. Ownership.

(a) Amount beneficially owned:

See line 9 of cover sheets.

NLV III is the record owner of 897,773 shares of Common Stock (the "NLV III Shares"). As the sole general partner of NLV III, NLVA III may be deemed to own beneficially the NLV III Shares. As the sole general partner of NLVA III and ultimate general partner of NLV III, NLV Management III may be deemed to own beneficially the NLV III Shares. As the individual managing directors of NLV Management III, each of the NLV Managing Directors also may be deemed to own beneficially the NLV III Shares.

Biopharma I is the record owner of 897,772 shares of Common Stock (the "Biopharma I Shares"). As the sole general partner of Biopharma I, NLBA I may be deemed to own beneficially the Biopharma I Shares. As the sole general partner of NLBA I and ultimate general partner of Biopharma I, NLV Management III may be deemed to own beneficially the Biopharma I Shares. As the individual managing directors of NLV Management III, each of the NLV Managing Directors also may be deemed to own beneficially the Biopharma I Shares.

In addition to the NLV III Shares and Biopharma I Shares, Ratcliffe is the direct owner of 8,475 shares of Common Stock underlying fully vested stock options.

(b) Percent of class:

See line 11 of cover sheets. The percentages set forth on the cover sheet for each Reporting Person are calculated based on 29,989,472 shares of Common Stock outstanding as of October 31, 2018, as reported on the Issuer's Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on November 13, 2018, plus in the case of Ratcliffe 8,475 shares of Common Stock subject to stock option awards that have been granted to Hunt in his capacity as a director of the Issuer.

- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: see line 5 of cover sheets.\*
  - (ii) Shared power to vote or to direct the vote: see line 6 of cover sheets.\*
  - (iii) Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.\*
  - (iv) Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.\*
- Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record and to the extent of their pecuniary interest therein.

#### Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

# Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Under certain circumstances set forth in the limited partnership agreements of each of NLV III, NLVA III, Biopharma I and NLBA I, and the limited liability company agreement of NLV Management III, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

Item 7. <u>Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

Item 10. <u>Certification</u>.

Not applicable.

Material to be Filed as Exhibits.

Exhibit 1 – Agreement Regarding Joint Filing of Schedule 13G.

# **SIGNATURES**

A ft.	v rosconsble inquire	and to the best of r	nry lineraledge and hel	of I cortified that the	information set forth in t	his statement is true	complete and correct
/A 116	i reasonable mounv	and to the pest of t	IIV KIIOWIEUSE AUG DEL	er, i cerniv mai me	annormanion sei torm in i	ins statement is true.	. Complete and Correct.

Date: February 12, 2019

NEW LEAF VENTURES II, L.P.

By: NEW LEAF VENTURE ASSOCIATES II, L.P.

Its General Partner

By: NEW LEAF VENTURE MANAGEMENT II, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF VENTURE ASSOCIATES II, L.P.

By: NEW LEAF VENTURE MANAGEMENT II, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF VENTURE MANAGEMENT II, L.L.C.

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

Vijay K. Lathi

Ronald M. Hunt

Liam T. Ratcliffe

/s/ Craig L. Slutzkin

\* Craig L. Slutzkin As attorney-in-fact

This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.

# **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

NEW LEAF BIOPHARMA OPPORTUNITIES I, L.P.

By: NEW LEAF BPO ASSOCIATES I, L.P.

Its General Partner

By: NEW LEAF VENTURE MANAGEMENT III, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF BPO ASSOCIATES I, L.P.

By: NEW LEAF VENTURE MANAGEMENT III, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

# AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Unum Therapeutics Inc.

Date: February 12, 2019

NEW LEAF VENTURES II, L.P.

By: NEW LEAF VENTURE ASSOCIATES II, L.P.

Its General Partner

By: NEW LEAF VENTURE MANAGEMENT II, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF VENTURE ASSOCIATES II, L.P.

By: NEW LEAF VENTURE MANAGEMENT II, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF VENTURE MANAGEMENT II, L.L.C.

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

Vijay K. Lathi

4

Ronald M. Hunt

Liam T. Ratcliffe

# NEW LEAF BIOPHARMA OPPORTUNITIES I, L.P.

By: NEW LEAF BPO ASSOCIATES I, L.P.

Its General Partner

By: NEW LEAF VENTURE MANAGEMENT III, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF BPO ASSOCIATES I, L.P.

By: NEW LEAF VENTURE MANAGEMENT III, L.L.C.

Its General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

/s/ Craig L. Slutzkin

\* Craig L. Slutzkin As attorney-in-fact

\* This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.